Comparing the efficacy of medications for ADHD using meta-analysis

MedGenMed Medscape General Medicine

Volumn 8, Issue 4, 2006, Pages

  Faraone, Stephen V ^a   Biederman, Joseph ^b,c   Spencer, Thomas J ^b,c   Aleardi, Megan ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; LONG ACTING DRUG; METHYLPHENIDATE; MODAFINIL; PEMOLINE; PLACEBO; SHORT ACTING DRUG;

ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; HYPERACTIVITY; IMPULSIVENESS; META ANALYSIS; OPPOSITIONAL DEFIANT DISORDER; SYSTEMATIC REVIEW; TREATMENT OUTCOME; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; RANDOMIZED CONTROLLED TRIAL;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 33749636443     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: Is it an American condition? World Psychiatry. 2003;2:104-113.
2. Volkow ND, Fowler JS, Wang G, et al. Mechanism of Action of methylphenidate: insights from PET imaging studies. J Atten Disord. 2002;6:S31-S44. Abstract
3. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21:RC121.
4. Greenhill LL, Pliszka S, Dulcan MK, et al. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2001;40:1352-1355. Abstract
5. Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin North Am. 2000;9:77-97.
6. Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;109:E39.
7. Wolraich M, Greenhill LL, Pelham W, et al. Randomized controlled trial of OROS methylphenidate qd in children with attention deficit/ hyperactivity disorder. Pediatrics. 2001;108:883-892. Abstract
8. Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention deficit hyperactivity disorder. Pediatrics. 2002;110:258-266. Abstract
9. Spencer T, Biederman J, Coffey B, et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2002;59:649-656. Abstract
10. Wilens T, Biederman J, Baldessarini R, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1996;35:1491-1501. Abstract
11. Biederman J, Baldessarini RJ, Wright V, et al. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry. 1989;28:777-784. Abstract
12. Conners K, Casat C, Guaiteri T, et al. Bupropion hydrochloride in attention deficit disorder withi hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996;35:1314-1321. Abstract
13. Casat CD, Pleasants DZ, Schroeder DH, et al. Bupropion in children with attention deficit disorder. Psychopharmacol Bull. 1989;25:198-201. Abstract
14. Casat CD, Pleasants DZ, Van Wyck Fleet J. A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmacol Bull. 1987;23:120-122. Abstract
15. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol. 2000;10:311-320. Abstract
16. Rugino TA, Copley TC. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J Am Acad Child Adolesc Psychiatry. 2001;40:230-235. Abstract
17. Maoi EM. Treatment of adult ADHD. In: NIMH Conference on Alternative Pharmacology of ADHD. Washington, DC; 1996.
18. Shekim WO, Davis LG, Bylund DB, et al. Platelet MAO in children with attention deficit disorder and hyperactivity: a pilot study. Am J Psychiatry. 1982; 139:936-938. Abstract
19. Spencer T, Biederman J. Non-stimulant treatment for attention-deficit/ hyperactivity disorder. J Atten Disord. 2002;6:S109-S119.
20. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:E83.
21. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112-120. Abstract
22. Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention deficit hyperactivity disorder. J Clin Psychopharmacol. 2004;54:24-29.
23. Faraone SV, Biederman J, Roe CM. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol. 2002;22:468-473. Abstract
24. Faraone S, Biederman J. Efficacy of Adderall, for attention-deficit/ hyperactivity disorder: a meta-analysis. J Atten Disord. 2002;6:69-75. Abstract
25. Schachter HM, Pham B, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165:1475-1488. Abstract
26. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders: a systematic review and European Treatment Guideline. Eur Child Adolesc Psychiatry. 2006 May 5; [Epub ahead of print].
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188. Abstract
28. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634. Abstract
29. Huber PJ. The behavior of maximum likelihood estimates under non-standard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. 1967;1:221-233.
30. Stata Corporation. Stata User's Guide: Release 7.0. College Station, Texas: Stata Corporation; 2001.
31. Wigal SB, Wigal TL, McGough JJ, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Attent Disord. 2005;9:275-289.
32. Faraone SV, Wigal S, Hodgkins P. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall Xr[R]) and atomoxetine (Strattera[R]) in school-aged children with attention-deficit/hyperactivity disorder. J Atten Disord. 2006; In press.
33. James RS, Sharp WS, Bastain TM, et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry. 2001;40:1268-1276. Abstract
34. Wilens T, McBurnett K, Bukstein O, et al. Multisite, controlled trial of OROS[R] methylphenidate (Concerta[R]) in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2006; 160:82-90. Abstract
35. Zeiner P, Bryhn G, Bjercke C, et al. Response to methylphenidate in boys with attention-deficit hyperactivity disorder. Acta Paediatr. 1999;88:298-303. Abstract
36. Conners CK, Taylor E. Pemoline, methylphenidate, and placebo in children with minimal brain dysfunction. Arch Gen Psychiatry. 1980;37:922-930. Abstract
37. Taylor E, Schachar R, Thorley G, et al. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med. 1987;17:121-143. Abstract
38. Klorman R, Brumaghim J, Fitzpatrick P, et al. Clinical and cognitive effects of methylphenidate on children with attention deficit disorder as a function of aggression oppositionality and age. J Abnorm Psychol. 1994;103:206-221. Abstract
39. Schachar R, Tannock R, Cunninggham C, et al. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry. 1997;36:754-763. Abstract
40. Manos MJ, Short EJ, Findling RL. Differential effectiveness of methylphenidate and Adderall in scholol-age youths with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999;38:813-819. Abstract
41. Bostic JQ, Biederman J, Spencer TJ, et al. Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short-term controlled trial. J Child Adolesc Psychopharmacol. 2000;10:205-216. Abstract
42. Pliszka SR, Browne RG, Olvera RL, et al. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2000;36:619-626. Abstract
43. Michelson D, Allen AJ, Busnor J, et al. Once daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder. a randomized placebo-controlled study. Am J Psychiatry. 2002; 159:1896-1901. Abstract
44. Biederman J, Heiligenstein J, Faries D, et al. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110:E75.
45. Spencer T, Heiligenstein J, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63:1140-1147. Abstract
46. Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once-daily, extended-release dosage form of methylphenidate hydrochloride, in children with ADHD. Pediatr Drugs. 2003;5:833-841.
47. Wigal S, Swanson JM, Feifel D, et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and D,L-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004;43:1406-1414. Abstract
48. Swanson JM, Greenhill LL, Lopez FA, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, doublel-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry. 2006;67:137-147. Abstract
49. Biederman J, Swanson J, Wigal S, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/ hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics. 2005;116:e777-e784. Abstract
50. Findling RL, McNamara NK, Youngstrom EA, et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:409-417. Abstract
51. Pelham WE, Burrows-Maclean L, Gnagy EM, et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol. 2005; 13:111-126. Abstract
52. Greenhill LL, Biederman J, Boellner SW, et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:503-511. Abstract
53. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004; 114:e1-e8. Abstract
54. Spencer T, Wilens T, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release Adderall XR in the management of attention-deficit hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:266-279. Abstract
55. Findling RL, Quinn D, Hatch SJ, et al. Comparison of the clinical efficacy of twice-daily Ritalin((R)) and once-daily Equasym (trade mark) XI with placebo in children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2006 Jun 21; [Epub ahead of print].